DURHAM, N.C., April 7, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission.
A copy of the Annual Report on Form 10-K is available to be viewed or downloaded from the Investors section of Argos's website at www.argostherapeutics.com. Argos stockholders or other interested parties may obtain a hard copy of the Annual Report on Form 10-K, free of charge, by contacting Argos's Investor Relations Department at: 4233 Technology Drive, Durham, NC 27704, or by email at: email@example.com.
About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The company also plans to report data from its Phase 2b trial of AGS-004 for the treatment of HIV in mid-2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com.
Source:Argos Therapeutics, Inc.